Results derived from both in vitro and in vivo experiments demonstrate that EMP3 regulates the PI3K/AKT pathway and promotes resistance to trastuzumab.<h4>Conclusions</h4>High EMP3 expression in HER2-enriched breast cancer predicts poor patient outcomes. This evidence concerns the gene AKT1 and breast carcinoma.